MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Abbott Laboratories

Geschlossen

BrancheGesundheitswesen

131.66 -0.32

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

131.22

Max

133.52

Schlüsselkennzahlen

By Trading Economics

Einkommen

7.6B

9.2B

Verkäufe

339M

11B

KGV

Branchendurchschnitt

17.363

63.778

EPS

1.34

Dividendenrendite

1.78

Gewinnspanne

84.099

Angestellte

114,000

EBITDA

82M

3B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+6.28% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.78%

2.39%

Nächstes Ergebnis

16. Apr. 2025

Nächste Dividendenausschüttung

15. Mai 2025

Nächstes Ex-Dividendendatum

15. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

7.8B

230B

Vorheriger Eröffnungskurs

131.98

Vorheriger Schlusskurs

131.66

Nachrichtenstimmung

By Acuity

33%

67%

94 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Abbott Laboratories Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Jan. 2025, 19:03 UTC

Ergebnisse

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

22. Jan. 2025, 18:20 UTC

Ergebnisse

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

22. Jan. 2025, 12:45 UTC

Ergebnisse

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

1. Nov. 2024, 14:15 UTC

Wichtige Markttreiber

Reckitt, Abbott Shares Rise After Baby-Formula Lawsuit Win -- Update

1. Nov. 2024, 10:10 UTC

Wichtige Markttreiber

Reckitt Shares Surge After Baby Formula Lawsuit Win

31. Okt. 2024, 23:57 UTC

Heiße Aktien

Stocks to Watch: Intel, Amazon.com, Abbott Laboratories, MasTec

31. Okt. 2024, 23:14 UTC

Wichtige Markttreiber

Abbott Laboratories Shares Rise After Baby-Formula Verdict

16. Okt. 2024, 12:03 UTC

Ergebnisse

Abbott Laboratories 3Q Sales Top Expectations

1. Feb. 2025, 18:14 UTC

Top News

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

22. Jan. 2025, 16:40 UTC

Top News
Ergebnisse

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

22. Jan. 2025, 15:20 UTC

Ergebnisse

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

22. Jan. 2025, 15:08 UTC

Ergebnisse

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22. Jan. 2025, 13:51 UTC

Ergebnisse

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

22. Jan. 2025, 13:39 UTC

Top News
Ergebnisse

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22. Jan. 2025, 12:02 UTC

Ergebnisse

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

22. Jan. 2025, 12:01 UTC

Ergebnisse

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

22. Jan. 2025, 12:01 UTC

Ergebnisse

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

22. Jan. 2025, 12:00 UTC

Ergebnisse

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

22. Jan. 2025, 12:00 UTC

Ergebnisse

Abbott Labs 4Q Net $9.23B >ABT

22. Jan. 2025, 12:00 UTC

Ergebnisse

Abbott Labs 4Q Sales $10.97B >ABT

22. Jan. 2025, 12:00 UTC

Ergebnisse

Abbott Labs 4Q Organic Sales Growth Up 8.8% >ABT

22. Jan. 2025, 12:00 UTC

Ergebnisse

Abbott Labs 4Q EPS $5.27 >ABT

22. Jan. 2025, 12:00 UTC

Ergebnisse

Abbott Labs 4Q Adj EPS $1.34 >ABT

22. Jan. 2025, 09:54 UTC

Heiße Aktien

Stocks to Watch Wednesday: Netflix, Oracle, Trump Media, Softbank -- WSJ

1. Nov. 2024, 17:33 UTC

Market Talk

Abbott's Baby-Formula Lawsuit Win Could Decrease Liabilities -- Market Talk

16. Okt. 2024, 14:21 UTC

Top News
Ergebnisse

Abbott Posts Solid Quarter. The Stock Is Rising. -- Barrons.com

16. Okt. 2024, 12:25 UTC

Ergebnisse

Abbott Labs Beats Q3 Sales And Earnings Expectations, Raises Full-Year Outlook -- MarketWatch

16. Okt. 2024, 12:02 UTC

Top News
Ergebnisse

Abbott Posts Solid Quarter. That Wasn't Enough to Lift Shares. -- Barrons.com

16. Okt. 2024, 11:59 UTC

Ergebnisse

Abbott Earnings Edge Past Q3 Views, Led By Medical Devices -- IBD

16. Okt. 2024, 11:37 UTC

Ergebnisse

Abbott Labs Sees 4Q Adj EPS $1.31-Adj EPS $1.37 >ABT

Peer-Vergleich

Kursveränderung

Abbott Laboratories Prognose

Kursziel

By TipRanks

6.28% Vorteil

12-Monats-Prognose

Durchschnitt 140.21 USD  6.28%

Hoch 158 USD

Tief 117 USD

Basierend auf 16 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Abbott Laboratories – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

16 ratings

14

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

126.38 / 132.65Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

94 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.